| scholarly article | Q13442814 |
| P2093 | author name string | Tsuyoshi Takahashi | |
| Mineo Kurokawa | |||
| Shigeru Chiba | |||
| Akira Hangaishi | |||
| Yasuhito Nannya | |||
| Yoichi Imai | |||
| Keisuke Kataoka | |||
| P433 | issue | 2 | |
| P304 | page(s) | 195-204 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. | |
| P478 | volume | 15 |
| Q36093703 | A Meta-Analysis for Effects of Elevated Pre-Transplantation Serum Ferritin on the Outcomes in Patients Undergoing Hematopoietic Stem Cell Transplantation |
| Q84278790 | A prognostic score with pretransplant serum ferritin and disease status predicts outcome following reduced-intensity SCT |
| Q42266529 | A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia |
| Q36431041 | Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? |
| Q37964938 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status |
| Q37635552 | Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content |
| Q45947630 | Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients. |
| Q41456272 | Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. |
| Q35864056 | Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation |
| Q45828141 | Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q35981569 | Does iron overload really matter in stem cell transplantation? |
| Q89444218 | Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis |
| Q43750571 | Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). |
| Q40269737 | Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients |
| Q42265794 | Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease |
| Q45132809 | Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement |
| Q33767314 | Hematopoietic stem cell transplantation for MDS. |
| Q35038813 | Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading? |
| Q84067122 | Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts |
| Q50592735 | Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation |
| Q40171404 | Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT). |
| Q50239379 | Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia |
| Q50995442 | Impact of pretransplant serum ferritin on outcome in adult patients receiving cord blood transplant for acute leukemia. |
| Q64263875 | Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia |
| Q38570614 | Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group |
| Q41914835 | Iron Overload in Patients Undergoing Hematopoietic Stem Cell Transplantation |
| Q64935199 | Iron Toxicity and Hemopoietic Cell Transplantation: Time to Change the Paradigm. |
| Q37842351 | Iron overload and allogeneic hematopoietic stem-cell transplantation. |
| Q33905984 | Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis |
| Q37637836 | Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. |
| Q33764777 | Liver iron content determination by magnetic resonance imaging |
| Q47138026 | MRI-based evaluation of multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Q38783289 | Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. |
| Q40072759 | Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation |
| Q44537606 | Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant |
| Q37837063 | Myelodysplasia in the Wellington region 2002-2007: disease incidence and treatment patterns. |
| Q37833060 | Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments |
| Q38287009 | Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment |
| Q33687277 | Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. |
| Q82577177 | Pre-SCT serum ferritin is a prognostic factor in adult AML, but not ALL |
| Q40201370 | Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation. |
| Q64113105 | Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis |
| Q84145304 | Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation |
| Q44457212 | Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies |
| Q59110232 | Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation |
| Q83071659 | Prognostic impact of serum ferritin concentration on survival following reduced-intensity conditioned allogeneic haemopoietic SCT |
| Q43856953 | Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation |
| Q38937601 | Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation |
| Q88622429 | Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation |
| Q51705519 | Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. |
| Q24626621 | Serum ferritin: Past, present and future |
| Q27010653 | Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy |
| Q47856320 | The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. |
| Q90437512 | The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis |
| Q38083570 | The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand? |
| Q45846541 | The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload |
| Q55114506 | Total body irradiation and iron chelation treatment are associated with pancreatic injury following pediatric hematopoietic stem cell transplantation. |
| Q38196963 | Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes |
| Q30240238 | Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens |
| Q45941460 | Transplantation in thalassemia: Revisiting the Pesaro risk factors 25 years later. |
Search more.